.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,167,574

« Back to Dashboard

Claims for Patent: 4,167,574

Title: N-phenyl-N-(4-piperidinyl)amides
Abstract:Novel compounds of the series of N-phenyl-N-(4-piperidinyl)amides having a (4,5-dihydro-4-R-5-oxo-1H-tetrazol-1-yl)alkyl or (4,5-dihydro-4-R-5-thioxo-1H-tetrazol-1-yl)alkyl substituent group in the 1-position of the piperidine nucleus, said compounds being useful as analgesic agents.
Inventor(s): Janssens; Frans (Putte, BE)
Assignee: Janssen Pharmaceutica, N.V. (BE)
Application Number:05/954,709
Patent Claims: 1. A chemical compound selected from the group consisting of a N-phenyl-N-(4-piperidinyl)amide derivative having the formula: ##STR23## and the pharmaceutically acceptable acid addition salts thereof, wherein:

R is a member selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, having 3 to 6 ring carbon atoms lower alkenyl, lower alkynyl, (lower alkyl)oxy(lower alkyl), aryl and aryl(lower alkyl);

R.sup.1 is a member selected from the group consisting of hydrogen, lower alkyl and aryl;

R.sup.2 is a member selected from the group consisting of hydrogen and lower alkyl;

R.sup.3 is a member selected from the group consisting of lower alkyloxycarbonyl, lower alkyloxymethyl and lower alkylcarbonyl;

R.sup.4 is a member selected from the group consisting of lower alkyl, cycloalkyl, having 3 to 6 ring carbon atoms lower alkenyl, lower alkyloxy and arylmethyl;

R.sup.5 is a member selected from the group consisting of hydrogen and lower alkyl;

R.sup.6 is a member selected from the group consisting of hydrogen, halo, lower alkyl, lower alkyloxy and trifluoromethyl;

Z is a member selected from the group consisting of O and S; and

n is the integer 0 or 1;

wherein said aryl as used in the foregoing definitions is selected from the group consisting of phenyl, substituted phenyl, thienyl and pyridinyl, said substituted phenyl having from 1 to 2 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, and trifluoromthyl.

2. A chemical compound selected from the group consisting of N-{1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethy l)-4-piperidinyl}-N-phenylpropanamide and the pharmaceutically acceptable acid addition salts thereof.

3. A chemical compound selected from the group consisting of methyl 1-[2-(4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl)ethyl]-4-[(1-oxopropyl)p henylamino]-4-piperidinecarboxylate and the pharmaceutically acceptable acid addition salts thereof.

4. A chemical compound selected from the group consisting of methyl 1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-[(1-oxopropyl)me thylamino]-4-piperidinecarboxylate and the pharmaceutically acceptable acid addition salts thereof.

5. A chemical compound selected from the group consisting of methyl 1-[2-(4,5-dihydro-5-oxo-4-propyl-1H-tetrazol-1-yl)ethyl]-4-[(1-oxopropyl)p henylamino]-4-piperidinecarboxylate and the pharmaceutically acceptable acid addition salts thereof.

6. A chemical compound selected from the group consisting of N-{1-[2-(4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymeth yl)-4-piperidinyl}-N-phenylpropanamide and the pharmaceutically acceptable acid addition salts thereof.

7. A chemical compound selected from the group consisting of N-{1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)-1-methylethyl]-4-(met hoxymethyl)-4-piperidinyl}-N-phenylpropanamide and the pharmaceutically acceptable acid addition salts thereof.

8. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of a N-phenyl-N-(4-piperidinyl)amide derivative having the formula: ##STR24## and the pharmaceutically acceptable acid addition salts thereof, wherein: R is a member selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, having 3 to 6 ring carbon atoms lower alkenyl, lower alkynyl, (lower alkyl)oxy(lower alkyl), aryl and aryl(lower alkyl);

R.sup.1 is a member selected from the group consisting of hydrogen, lower alkyl and aryl;

R.sup.2 is a member selected from the group consisting of hydrogen and lower alkyl;

R.sup.3 is a member selected from the group consisting of lower alkyloxycarbonyl, lower alkyloxymethyl and lower alkylcarbonyl;

R.sup.4 is a member selected from the group consisting of lower alkyl, cycloalkyl, having 3 to 6 ring carbon atoms lower alkenyl, lower alkyloxy and arylmethyl;

R.sup.5 is a member selected from the group consisting of hydrogen and lower alkyl;

R.sup.6 is a member selected from the group consisting of hydrogen, halo, lower alkyl, lower alkyloxy and trifluoromethyl;

Z is a member selected from the group consisting of O and S; and

n is the integer 0 or 1;

wherein said aryl as used in the foregoing definitions is selected from the group consisting of phenyl, substituted phenyl, thienyl and pyridinyl, said substituted phenyl having from 1 to 2 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, and trifluoromethyl.

9. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of N-{1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethy l)-4-piperidinyl}-N-phenylpropanamide and the pharmaceutically acceptable acid addition salts thereof.

10. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of methyl 1-[2-(4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl)ethyl]-4-[(1-oxopropyl)p henylamino]-4-piperidinecarboxylate and the pharmaceutically acceptable acid addition salts thereof.

11. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of methyl 1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-[(1-oxopropyl)ph enylamino]-4-piperidinecarboxylate and the pharmaceutically acceptable acid addition salts thereof.

12. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of methyl 1-[2-(4,5-dihydro-5-oxo-4-propyl-1H-tetrazol-1-yl)ethyl]-4-[(1-oxopropyl)p henylamino]-4-piperidinecarboxylate and the pharmaceutically acceptable acid addition salts thereof.

13. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of N-{1-[2-(4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymeth yl)-4-piperidinyl}-N-phenylpropanamide and the pharmaceutically acceptable acid addition salts thereof.

14. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective analgesic amount of a compound selected from the group consisting of N-{1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)-methylethyl]-4-(metho xymethyl)-4-piperidinyl}-N-phenylpropanamide and the pharmaceutically acceptable acid addition salts thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc